Kaleido Biosciences, Inc. (KLDO)

Apr 18, 2022 - KLDO was delisted (reason: ceased operations)
0.290
0.000 (0.00%)
At close: Apr 14, 2022 12:00 AM
0.300
0.010 (3.552%)
After-hours:Apr 14, 2022 7:59 PM EDT

Company Description

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies.

The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease.

It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases.

The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Kaleido Biosciences, Inc.
Kaleido Biosciences Logo
CountryUnited States
Founded2015
IPO DateFeb 28, 2019
IndustryPharmaceuticals
SectorHealth Care
Employees82

Contact Details

Address:
65 Hayden Avenue
Lexington, MA 02421
United States
Phone617 674 9000
Websitekaleido.com

Stock Details

Ticker SymbolKLDO
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
IPO Price$15.00
CIK Code0001751299

Key Executives

NamePosition
Jerald Korn J.D.Consultant
Kimberly HocknellSenior Vice President of Technical Operations
Susan Stewart J.D.Chief Regulatory Affairs ? Advisor
Dr. Mark A. Wingertzahn Ph.D.Senior Vice President of Research & Development and Head of Development
Dr. Alison Long M.D., Ph.D.Chief Medical Officer

Latest SEC Filings

DateTypeTitle
May 10, 2022SC 13G/AStatement of acquisition of beneficial ownership by individuals
May 6, 202215-12BSecurities registration termination [Section 12(b)]
May 2, 2022EFFECTNotice of Effectiveness
Apr 25, 2022S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Apr 25, 2022S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Apr 25, 2022S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Apr 25, 2022POS AMPost-Effective amendments for registration statement
Apr 18, 202225Notification of the removal from listing and registration of matured, redeemed or retired securities
Apr 8, 20228-KCurrent report
Mar 31, 2022NT 10-KNotification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
View All SEC Filings